What is the enterprise value of KIADIS PHARMA? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as KIADIS PHARMA, is its stock price multiplied by the total number of shares outstanding, calculating KIADIS PHARMA's enterprise value requires a different approach. It uses KIADIS PHARMA's balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
KIADIS PHARMA NV latest Real Value cannot be determined due to lack of data. The recent price of KIADIS PHARMA NV is €0.0. Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Our model forecasts the value of KIADIS PHARMA NV from inspecting the firm fundamentals such as Return On Asset of (24.76) %, price to book of 2.83 X, and Current Valuation of 91.9 M as well as reviewing its technical indicators and Probability Of Bankruptcy. In general, we recommend acquiring undervalued equities and dropping overvalued equities since, in the future, asset prices and their ongoing real values will come together.
KIADIS PHARMA Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as KIADIS PHARMA's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.

KIADIS PHARMA Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining KIADIS PHARMA's current stock value. Our valuation model uses many indicators to compare KIADIS PHARMA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across KIADIS PHARMA competition to find correlations between indicators driving KIADIS PHARMA's intrinsic value. More Info.
KIADIS PHARMA NV is number one stock in beta category among related companies. It is number one stock in price to book category among related companies fabricating about  1.22  of Price to Book per Beta. . Comparative valuation analysis is a catch-all model that can be used if you cannot value KIADIS PHARMA by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for KIADIS PHARMA's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the KIADIS PHARMA's earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates KIADIS PHARMA's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in KIADIS PHARMA and how it compares across the competition.
Check out Trending Equities. Note that the KIADIS PHARMA NV information on this page should be used as a complementary analysis to other KIADIS PHARMA's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Other Tools for KIADIS Stock

When running KIADIS PHARMA NV price analysis, check to measure KIADIS PHARMA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy KIADIS PHARMA is operating at the current time. Most of KIADIS PHARMA's value examination focuses on studying past and present price action to predict the probability of KIADIS PHARMA's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move KIADIS PHARMA's price. Additionally, you may evaluate how the addition of KIADIS PHARMA to your portfolios can decrease your overall portfolio volatility.
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Bond Directory
Find actively traded corporate debentures issued by US companies
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device